In this article
Culture-expanded Wharton’s jelly-derived mesenchymal stromal cells (WJ-MSCs) are not currently FDA-approved for routine commercial treatment in Florida or elsewhere in the United States.
Limited investigational access exists. Florida’s stem-cell law does not turn an unapproved expanded-cell product into an FDA-approved treatment. [1, 2, 5, 6]
For patients comparing a Florida clinic with OmniStem in Punta Cana, the important question is what the proposed treatment actually contains. Umbilical cord tissue, tissue matrix, and isolated, culture-expanded MSCs can share an origin while representing different preparations.
What culture expansion means
Wharton’s jelly is the connective tissue surrounding the umbilical cord’s blood vessels. It contains a structural matrix as well as cells. In a culture-expanded preparation, MSCs are isolated and multiplied under controlled laboratory conditions. The resulting cell population can be characterized and prepared at a specified dose. A processed tissue allograft does not establish the same composition simply because its label says Wharton’s jelly. [8, 10]
At OmniStem, our approach uses Wharton’s jelly-derived UC-MSCs expanded in laboratory culture. We follow Good Manufacturing Practice (GMP) standards and use a master cell bank to support standardization. The bank provides a characterized starting cell source for production. Third-party laboratories verify cell viability and microbiological quality, supporting a documented preparation for treatment.
Why minimal manipulation matters
What Florida law actually permits
Tissue matrix and expanded cells are different preparations
Acellular preparations contain no living cells. Other tissue preparations can retain residual cells without constituting a defined MSC product. Claims about collagen, growth factors, or cushioning therefore do not answer the question of how many viable, identified MSCs a patient will receive. Each product’s intended use and processing require their own regulatory assessment. [4, 8]
A January 2026 paper examined six commercial, cryopreserved Wharton’s jelly matrix specimens. Reported cell viability ranged from 0% to 19.1%, with rare viable MSCs. This small laboratory analysis did not test every marketed product or compare patient outcomes. Its authors disclosed employment or consulting relationships with its funders, TAM Global and Cellular Performance Institute. [8]
Those findings should not be generalized to all frozen cells. Ryoncil, an FDA-approved bone marrow-derived MSC therapy for a specific pediatric graft-versus-host disease indication, is supplied cryopreserved. It is a different product from WJ-MSCs, but illustrates why freezing alone cannot establish whether a cell preparation is effective. [9]
Where investigational access fits
Expanded WJ-MSCs may be accessible through trials conducted under an effective Investigational New Drug (IND) application. FDA expanded access can also permit treatment outside a trial for eligible patients with serious or immediately life-threatening conditions and no comparable satisfactory alternative. [5, 6]
A separate federal Right to Try pathway has strict patient and product eligibility requirements, including completed Phase 1 testing. These pathways do not create ordinary retail availability. An IND number alone is not proof that a particular clinic, product, protocol, and patient are covered. Ask for documentation of the pathway being relied upon. [6, 7]
What to ask before choosing a provider
• Product identity: Is this a tissue matrix preparation or isolated, culture-expanded MSCs?
• Actual dose: How many viable, identified MSCs are in the administered preparation, and when was that measured?
• Manufacturing: What are the cell-bank system, passage history, freezing history, and batch release criteria?
• Documentation: Can the provider explain the applicable authorization, product identity testing, and contamination testing?
• Clinical plan: What evidence supports the proposed use, what are the risks and alternatives, and how is follow-up handled?
The OmniStem approach
OmniStem provides culture-expanded Wharton’s jelly UC-MSC therapies in Punta Cana within the Dominican Republic’s legal and regulatory framework. Our Ministry of Public Health clinical authorization expressly includes cellular therapy. Our manufacturing approach combines GMP standards, a master cell bank for standardization, and third-party verification of cell viability and microbiological quality.
Our medical team reviews each patient’s history and goals before proposing a treatment plan. We invite patients and their physicians to discuss the cells, supporting documentation, anticipated benefits, risks, and follow-up. Culture expansion and manufacturing controls support a defined product; they do not guarantee a clinical outcome.
Explore your options with OmniStem in Punta Cana. Request a physician-led case review at care.omnistem.com/begin or contact info@omnistem.com.
Sources and publication details
[1] FDA approved cellular and gene therapy products
[2] Florida Statutes 458.3245 Stem cell therapy
[3] FDA final rule 66 FR 5447 at 5457 Comment 27 January 19 2001
[4] FDA guidance Minimal Manipulation and Homologous Use July 2020
[5] FDA warning letter to Invitrx Therapeutics November 9 2022
[6] FDA Expanded Access and eligibility
[7] FDA Right to Try eligibility and limitations
[8] Marleau AM et al. Critical evaluation of compositions and clinical relevance of Wharton’s jelly-derived biologics.
[9] FDA Ryoncil prescribing information
[10] OmniStem Sources and Standards
Manufacturing context: OmniStem management confirmation of GMP standards, master cell bank use, third-party laboratory verification of viability and microbiological quality, and operation within the Dominican legal framework, September 11, 2026. Supporting framework: WHO good manufacturing practices for biological products, WHO Technical Report Series 999, Annex 2, section 8, supplied source document.
Web sources checked September 11, 2026. This article explains product and regulatory distinctions. Medical suitability and outcomes depend on the individual case.
